The sustained-release profile of the test product, compared to reference product, will provide longer-lasting therapeutic effects from a single daily dose, according to the company. Nutriventia added that the pharmacokinetic study reports for first time, the successful plasma estimation of withanolide A and 12-deoxywithastraamonolide, the major phytoactives of ashwagandha.